BlueCrest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$304K	–	281
2023 Q1	$304K	Buy	+3,000	New	+$312K	0.01%	209
2019 Q4	–	Sell	-3,895	Closed	-$351K	–	506
2019 Q3	$351K	Buy	+3,895	New	+$364K	0.02%	332
2018 Q4	–	Sell	-21,468	Closed	-$2.64M	–	1223
2018 Q3	$2.64M	Buy	+21,468	New	+$2.44M	0.07%	201
2018 Q1	–	Sell	-17,176	Closed	-$1.33M	–	1586
2017 Q4	$1.33M	Sell	17,176 -8,005	-32%	-$546K	0.04%	333
2017 Q3	$1.54M	Buy	25,181 +13,081	+108%	+$690K	0.06%	288
2017 Q2	$557K	Buy	+12,100	New	+$587K	0.02%	570
2016 Q4	–	Sell	-4,529	Closed	-$229K	–	806
2016 Q3	$229K	Sell	4,529 -3,044	-40%	-$152K	0.01%	645
2016 Q2	$344K	Sell	7,573 -15,462	-67%	-$712K	0.01%	646
2016 Q1	$911K	Buy	+23,035	New	+$914K	0.06%	397